{
    "xml": "<topic id=\"PHP1552\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/prasugrel\" basename=\"prasugrel\" title=\"PRASUGREL\">\n<title>PRASUGREL</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1146\" namespace=\"/interactions/list-of-drug-interactions/prasugrel\">Prasugrel</xref>\n</p>\n<data name=\"vtmid\">443312008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_119773927\" title=\"Antiplatelets\">Antiplatelets</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP59625\" outputclass=\"indicationsAndDose\" rev=\"1.36\" parent=\"/drugs/prasugrel\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">In combination with aspirin for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult 18&#8211;74 years (body-weight up to 60 kg)</p>\n<p>Initially 60&#8239;mg for 1 dose, then 5&#8239;mg once daily usually for up to 12 months.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult 18&#8211;74 years (body-weight 60 kg and above)</p>\n<p>Initially 60&#8239;mg for 1 dose, then 10&#8239;mg once daily usually for up to 12 months.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult 75 years and over</p>\n<p>Initially 60&#8239;mg for 1 dose, then 5&#8239;mg once daily usually for up to 12 months.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Patients undergoing coronary angiography within 48 hours of admission for unstable angina or NSTEMI</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 60&#8239;mg, to be administered at the time of percutaneous coronary intervention to minimise the risk of bleeding, maintenance dose of 10&#8239;mg or 5&#8239;mg daily should then be selected as appropriate.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Alternative to clopidogrel in certain patients undergoing percutaneous coronary intervention</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>60&#8239;mg.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59754\" outputclass=\"contraindications\" rev=\"1.6\" parent=\"/drugs/prasugrel\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Active bleeding</ph>; <ph outputclass=\"contraindication\">history of stroke or transient ischaemic attack</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59776\" outputclass=\"cautions\" rev=\"1.7\" parent=\"/drugs/prasugrel\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Body-weight less than 60 kg</ph>; <ph outputclass=\"caution\">discontinue at least 7 days before elective surgery if antiplatelet effect not desirable</ph>; <ph outputclass=\"caution\">elderly</ph>; <ph outputclass=\"caution\">patients at increased risk of bleeding (e.g. from recent trauma, surgery, gastro-intestinal bleeding, or active peptic ulcer disease)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59591\" outputclass=\"interactions\" rev=\"1.9\" parent=\"/drugs/prasugrel\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (prasugrel).</p>\n<p>Caution with concomitant use of drugs that increase risk of bleeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59482\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/prasugrel\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anaemia</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal haemorrhage</ph>; <ph outputclass=\"sideEffect\">haematoma</ph>; <ph outputclass=\"sideEffect\">haematuria</ph>; <ph outputclass=\"sideEffect\">haemorrhage</ph>; <ph outputclass=\"sideEffect\">intracranial haemorrhage</ph>; <ph outputclass=\"sideEffect\">rash</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Angioedema</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Thrombocytopenia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Thrombotic thrombocytopenic purpura</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59789\" outputclass=\"allergyAndCrossSensitivity\" rev=\"1.20\" parent=\"/drugs/prasugrel\">\n<title>Allergy and cross-sensitivity</title>\n<body>\n<section outputclass=\"allergyAndCrossSensitivityCrossSensitivity\">\n<sectiondiv>\n<p>Caution in patients with history of hypersensitivity reactions to thienopyridines (e.g. clopidogrel).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59563\" outputclass=\"pregnancy\" parent=\"/drugs/prasugrel\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises use only if potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59784\" outputclass=\"breastFeeding\" parent=\"/drugs/prasugrel\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59707\" outputclass=\"hepaticImpairment\" parent=\"/drugs/prasugrel\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use with caution in moderate impairment&#8212;increased risk of bleeding.</p>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59532\" outputclass=\"renalImpairment\" parent=\"/drugs/prasugrel\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use with caution&#8212;increased risk of bleeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59373\" outputclass=\"nationalFunding\" rev=\"1.34\" parent=\"/drugs/prasugrel\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA317</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (July 2014)</p>\r\n<p>Prasugrel 10&#8239;mg in combination with aspirin is recommended as an option, within its marketing authorisation, for preventing atherothrombotic events in adults with acute coronary syndrome (unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI) or ST segment elevation myocardial infarction (STEMI)) having primary or delayed percutaneous coronary intervention.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA317\">www.nice.org.uk/TA317</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium </i>has advised (August 2009) that prasugrel (<i>Efient</i>\r\n<tm tmtype=\"reg\"/>), in combination with aspirin, be accepted for restricted use within NHS Scotland for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention who are eligible to receive the 10&#8239;mg dose of prasugrel.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP1552-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/prasugrel\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77091\" title=\"Tablet\" namespace=\"/drugs/prasugrel/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78144\" namespace=\"/treatment-summaries/acute-coronary-syndromes\" title=\"Acute coronary syndromes\" count=\"4\" rel=\"backlink\">Acute coronary syndromes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78186\" namespace=\"/treatment-summaries/antiplatelet-drugs\" title=\"Antiplatelet drugs\" count=\"3\" rel=\"backlink\">Antiplatelet drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1146\" namespace=\"/interactions/list-of-drug-interactions/prasugrel\" title=\"Prasugrel\" count=\"1\" rel=\"link\">Prasugrel</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77091\" namespace=\"/drugs/prasugrel/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP1552",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/prasugrel",
    "basename": "prasugrel",
    "title": "PRASUGREL",
    "interactants": [
        {
            "id": "bnf_int_1146",
            "label": "Prasugrel"
        }
    ],
    "vtmid": "443312008",
    "drugClassification": [
        "Antiplatelets"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "In combination with aspirin for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention",
                        "html": "In combination with aspirin for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 60 mg for 1 dose, then 5 mg once daily usually for up to 12 months.",
                        "html": "<p>Initially 60&#8239;mg for 1 dose, then 5&#8239;mg once daily usually for up to 12 months.</p>",
                        "ageGroup": "18&#8211;74 years (body-weight up to 60 kg)"
                    },
                    {
                        "textContent": "Initially 60 mg for 1 dose, then 10 mg once daily usually for up to 12 months.",
                        "html": "<p>Initially 60&#8239;mg for 1 dose, then 10&#8239;mg once daily usually for up to 12 months.</p>",
                        "ageGroup": "18&#8211;74 years (body-weight 60 kg and above)"
                    },
                    {
                        "textContent": "Initially 60 mg for 1 dose, then 5 mg once daily usually for up to 12 months.",
                        "html": "<p>Initially 60&#8239;mg for 1 dose, then 5&#8239;mg once daily usually for up to 12 months.</p>",
                        "ageGroup": "75 years and over"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Patients undergoing coronary angiography within 48 hours of admission for unstable angina or NSTEMI",
                        "html": "Patients undergoing coronary angiography within 48 hours of admission for unstable angina or NSTEMI"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 60 mg, to be administered at the time of percutaneous coronary intervention to minimise the risk of bleeding, maintenance dose of 10 mg or 5 mg daily should then be selected as appropriate.",
                        "html": "<p>Initially 60&#8239;mg, to be administered at the time of percutaneous coronary intervention to minimise the risk of bleeding, maintenance dose of 10&#8239;mg or 5&#8239;mg daily should then be selected as appropriate.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Alternative to clopidogrel in certain patients undergoing percutaneous coronary intervention",
                        "html": "Alternative to clopidogrel in certain patients undergoing percutaneous coronary intervention"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "60 mg.",
                        "html": "<p>60&#8239;mg.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Active bleeding",
                "html": "Active bleeding"
            },
            {
                "type": "contraindications",
                "textContent": "history of stroke or transient ischaemic attack",
                "html": "history of stroke or transient ischaemic attack"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Body-weight less than 60 kg",
                "html": "Body-weight less than 60 kg"
            },
            {
                "type": "cautions",
                "textContent": "discontinue at least 7 days before elective surgery if antiplatelet effect not desirable",
                "html": "discontinue at least 7 days before elective surgery if antiplatelet effect not desirable"
            },
            {
                "type": "cautions",
                "textContent": "elderly",
                "html": "elderly"
            },
            {
                "type": "cautions",
                "textContent": "patients at increased risk of bleeding (e.g. from recent trauma, surgery, gastro-intestinal bleeding, or active peptic ulcer disease)",
                "html": "patients at increased risk of bleeding (e.g. from recent trauma, surgery, gastro-intestinal bleeding, or active peptic ulcer disease)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (prasugrel).\n\nCaution with concomitant use of drugs that increase risk of bleeding.",
                "html": "<p>Appendix 1 (prasugrel).</p><p>Caution with concomitant use of drugs that increase risk of bleeding.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Anaemia",
                        "html": "Anaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastro-intestinal haemorrhage",
                        "html": "gastro-intestinal haemorrhage",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "haematoma",
                        "html": "haematoma",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "haematuria",
                        "html": "haematuria",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "haemorrhage",
                        "html": "haemorrhage",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "intracranial haemorrhage",
                        "html": "intracranial haemorrhage",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Angioedema",
                        "html": "Angioedema",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hypersensitivity reactions",
                        "html": "hypersensitivity reactions",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Thrombocytopenia",
                        "html": "Thrombocytopenia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Thrombotic thrombocytopenic purpura",
                        "html": "Thrombotic thrombocytopenic purpura",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "allergyAndCrossSensitivity": {
        "crossSensitivity": [
            {
                "type": "crossSensitivity",
                "textContent": "Caution in patients with history of hypersensitivity reactions to thienopyridines (e.g. clopidogrel).",
                "html": "<p>Caution in patients with history of hypersensitivity reactions to thienopyridines (e.g. clopidogrel).</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises use only if potential benefit outweighs risk.",
                "html": "<p>Manufacturer advises use only if potential benefit outweighs risk.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid&#8212;no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use with caution in moderate impairment&#8212;increased risk of bleeding.\n\nAvoid in severe impairment.",
                "html": "<p>Use with caution in moderate impairment&#8212;increased risk of bleeding.</p><p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use with caution&#8212;increased risk of bleeding.",
                "html": "<p>Use with caution&#8212;increased risk of bleeding.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA317",
                        "label": "www.nice.org.uk/TA317"
                    }
                ],
                "fundingIdentifier": "NICE TA317",
                "textContent": "Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (July 2014) Prasugrel 10 mg in combination with aspirin is recommended as an option, within its marketing authorisation, for preventing atherothrombotic events in adults with acute coronary syndrome (unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI) or ST segment elevation myocardial infarction (STEMI)) having primary or delayed percutaneous coronary intervention.\n\nwww.nice.org.uk/TA317",
                "html": "<p outputclass=\"title\">Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (July 2014)</p> <p>Prasugrel 10&#8239;mg in combination with aspirin is recommended as an option, within its marketing authorisation, for preventing atherothrombotic events in adults with acute coronary syndrome (unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI) or ST segment elevation myocardial infarction (STEMI)) having primary or delayed percutaneous coronary intervention.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA317\">www.nice.org.uk/TA317</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77091",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78144",
                "label": "Acute coronary syndromes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78186",
                "label": "Antiplatelet drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1146",
                "label": "Prasugrel",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77091",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}